Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Warning! GuruFocus has detected 6 Warning Signs with ORCL. As of 2025-02-25, Eli Lilly and Co's intrinsic value as calculated by the Discounted Earnings model is $271.69. It's currently trading at ...

Lilly looks poised to hit a $1 trillion market value Shares of Eli Lilly haven't been doing well in recent months, but over the long run, I think they will more than recover. This is a company ...

The bottom line: We're raising our Lilly fair value estimate to $620 from $580 to account for higher long-term growth from the oncology and immunology portfolio, which supports the firm's wide ...

When value trading, my threshold for a Buy rating is now an annual return expectation of 22.5%, and the price for Eli Lilly has risen 10% already since my last analysis in January. However ...